Barclays Sticks to Their Buy Rating for Teva Pharmaceutical (TEVA)
In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...
BioPharma Dive21h
Sanofi, Teva add to case for new bowel disease drug
Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.
FiercePharma23h
Eli Lilly, Novo Nordisk lead revenue boom in the 'always tricky' Q4
Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen ...
Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease
Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with ...
FierceBiotech1d
Sanofi shows how $500M bowel disease bet compares to Merck and Roche's rival assets
Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that ...
GlobalData on MSN1d
Teva and Alvotech launch ustekinumab biosimilar injection in US
Teva Pharmaceuticals and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...
Teva holds a pharmaceutical update conference call
Conference call to discuss new data presented for duvakitug (Anti-TL1A) positive Phase 2b results at the 20th Annual Congress of the European ...
Hosted on MSN3d
Teva Pharma and Alvotech launch biosimilar to J&J's Stelara in US
(Reuters) -Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States, the second in a wave of near-copies of ...